Don’t become a mere recorder of facts, but try to penetrate the mystery of their origin--Ivan Pavlov
Leaning into the silver lining a bit more, my consumption of podcasts tripled. I didn’t become brilliant or anything but my questions were definitely better. Nothing makes you brilliant-adjacent faster than better questions.
For example, I often facilitate data discussions about Anti-PD-1 Therapies. These are straightforward discussions because you can access de-identified open source data from the US FDA Adverse Event Reporting System (FAERS). Many of the pharma types in my workshops are focused on the profits made from the leading drugs. Executives and marketing agencies dissect the positioning and marketing strategies of the branded drugs in the space and point to strategies you can emulate.
I like to talk about the patients. These are highly toxic drugs being introduced into sick patients. What are the risks? What are reasonable side effects to expect? How does overall survival compare to standard therapies? Are there clues as to which patients might have better outcomes?
My point here isn’t to discuss the actual data although we can if that is of interest. A recent podcast did an interesting job walking through the latest research utilizing a creative but impactful study.
I like to share examples of how to add a deeper insight by looking at a variety of data perspectives and resources.
Thanks for reading along!